Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists

OBJECTIVES: To compare serum anti-Müllerian hormone (AMH) levels among girls with central precocious puberty (CPP) receiving gonadotropin-releasing hormone agonist (GnRH-a) treatment and prepubertal and pubertal controls, and to investigate the association between AMH levels and pubertal suppression. METHODS: This cross-sectional study included 50 GnRH-a-treated girls with CPP and 25 prepubertal and 25 pubertal controls. Pubertal suppression was assessed using three predefined criteria: reduced bone age advancement, stable/regressed breast Tanner stage, and annual height velocity ≤6 cm/year. Patients meeting 2-3 or 0-1 criteria were classified as having an adequate or inadequate pubertal suppression profile, respectively. RESULTS: AMH differed significantly among the groups (p=0.002) and was higher in CPP [2.93 (2.24-4.24) µg/L] than in pubertal controls [1.60 (1.05-2.72) µg/L; Bonferroni-adjusted p=0.003]. Among patients with CPP, 76 % had an adequate pubertal suppression profile. AMH was higher in patients with an adequate than an inadequate pubertal suppression profile [3.67 (2.53-4.70) vs. 2.56 (1.98-2.94) µg/L; p=0.028]. Suppression profiles also differed in anthropometric measures and GnRH-a exposure. Higher AMH was associated with stable/regressed breast Tanner stage (p=0.014) and height velocity ≤6 cm/year (p=0.034), but not reduced bone age advancement (p=0.763). AMH discriminated adequate and inadequate pubertal suppression profiles (AUC 0.714, 95 % CI 0.553-0.875; p=0.009); an exploratory threshold of ≥3.00 μg/L yielded 60.5 % sensitivity and 83.3 % specificity. CONCLUSIONS: Serum AMH was higher in GnRH-a-treated girls with CPP than in pubertal controls and was associated with an adequate pubertal suppression profile. AMH may be a complementary biomarker for assessing pubertal suppression, although prospective validation is required.

Authors

Institutions

Publication Details

Journal
Journal of Pediatric Endocrinology and Metabolism
Published
2026-11-19
DOI
https://doi.org/10.1515/jpem-2026-0747
Primary Topic
Hypothalamic control of reproductive hormones
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists

Seda Erişen Karaca, Sezer Acar, Cemil Koçyiğit, Tugce Candan Celik et al.
2 links
Journal of Pediatric Endocrinology and Metabolism
Hypothalamic control of reproductive hormones
article

Anti-Müllerian hormone as a potential marker of pubertal suppression in girls with central precocious puberty treated with GnRH agonists

Seda Erişen Karaca, Sezer Acar, Cemil Koçyiğit, Tugce Candan Celik, Tugce Tiric Cevizbas
article en

Abstract

OBJECTIVES: To compare serum anti-Müllerian hormone (AMH) levels among girls with central precocious puberty (CPP) receiving gonadotropin-releasing hormone agonist (GnRH-a) treatment and prepubertal and pubertal controls, and to investigate the association between AMH levels and pubertal suppression. METHODS: This cross-sectional study included 50 GnRH-a-treated girls with CPP and 25 prepubertal and 25 pubertal controls. Pubertal suppression was assessed using three predefined criteria: reduced bone age advancement, stable/regressed breast Tanner stage, and annual height velocity ≤6 cm/year. Patients meeting 2-3 or 0-1 criteria were classified as having an adequate or inadequate pubertal suppression profile, respectively. RESULTS: AMH differed significantly among the groups (p=0.002) and was higher in CPP [2.93 (2.24-4.24) µg/L] than in pubertal controls [1.60 (1.05-2.72) µg/L; Bonferroni-adjusted p=0.003]. Among patients with CPP, 76 % had an adequate pubertal suppression profile. AMH was higher in patients with an adequate than an inadequate pubertal suppression profile [3.67 (2.53-4.70) vs. 2.56 (1.98-2.94) µg/L; p=0.028]. Suppression profiles also differed in anthropometric measures and GnRH-a exposure. Higher AMH was associated with stable/regressed breast Tanner stage (p=0.014) and height velocity ≤6 cm/year (p=0.034), but not reduced bone age advancement (p=0.763). AMH discriminated adequate and inadequate pubertal suppression profiles (AUC 0.714, 95 % CI 0.553-0.875; p=0.009); an exploratory threshold of ≥3.00 μg/L yielded 60.5 % sensitivity and 83.3 % specificity. CONCLUSIONS: Serum AMH was higher in GnRH-a-treated girls with CPP than in pubertal controls and was associated with an adequate pubertal suppression profile. AMH may be a complementary biomarker for assessing pubertal suppression, although prospective validation is required.

Journal of Pediatric Endocrinology and Metabolism
Izmir University (TR), Sağlık Bilimleri Üniversitesi (TR), Izmir Tepecik Eğitim ve Araştırma Hastanesi (TR)
Good health and well-being
Hypothalamic control of reproductive hormones
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon